洞察市场格局
解锁药品研发情报

免费客服电话

18983288589

医药数据查询

生物医药全产业链数据服务平台

企业版官网

掌上数据

打开微信扫一扫

数据开放平台

产品矩阵

首页

个人版

企业版

高校版

摩熵咨询

咨询服务

资源大厅

资讯

摩熵原创

摩熵视野

会议会展

市场洞察

临床进展

投融资

关于我们

请输入关键词

历史搜索

热门搜索

GLP-1

英文版 | 创新研发进展不断！华东医药将携十大创新药项目亮相国际大会

ADA H1 Huadong Medicine

华东医药股份有限公司

04/15

查看原文

Guided by its corporate philosophy of Scientific Research-based and Patient-centered', Huadong Medicine has dedicated itself to advancing treatments in cancer, autoimmune disorders, and chronic metabolic diseases." By continuously increasing R&D investment and actively promoting the progress of clinical trials, we have achieved several significant milestones. In particular, ten of our proprietary research results are scheduled for presentation at major global conferences in the first half of 2025, including the annual meetings of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Diabetes Association (ADA) and European Association for the Study of the Liver (EASL). These presentations will highlight our pioneering contributions to global healthcare innovation.

2025AACR

The 2025 Annual Meeting of the American Association for Cancer Research (AACR) will be held from 25 to 30 April in Chicago, USA. As the world's oldest and largest cancer research conference, the AACR will bring together leading scientists, pharmaceutical innovators, and research institutions to highlight high-impact cancer studies and cutting-edge therapeutic advances, showcasing the latest breakthroughs in oncology. At this premier event, Huadong Medicine will make a groundbreaking debut with five novel proprietary therapies selected for poster presentations, including HDM2022: A first-in-class GSPT1 molecular glue degrader with potent anti-tumour activity；HDM2006: The first oral HPK1-targeting PROTAC (proteolysis-targeting chimera) for hematopoietic progenitor kinase inhibition；Three next-generation ADCs, HDM2012: Targeting MUC17 for gastrointestinal cancers, HDM2017: Targeting CDH17 for metastatic solid tumours, HDM2020: An FGFR2b-specific ADC designed for precision therapy in resistant malignancies. These innovations underscore Huadong Medicine's achievements in pioneering transformative oncology solutions.

2025H1: Posters at AACR
April 27th 2:00PM-5:00PM	Poster Section:10 Board Number:13 Preclinical development of HDM2020, a novel ADC targeting FGFR2b, in gastric cancer (GC) and squamous non-small cell lung cancer (sq-NSCLC) xenograft models Abstract No. 245
	Poster Section:15 Board Number:8 Translational studies of HDM2012, a novel topoisomerase inhibitor ADC targeting MUC17, in patient derived GC, CRC, PDAC tumor models Abstract No. 316
	Poster Section:15 Board Number:9 Discovery of HDM2017, a CDH17-targeting ADC for colorectal cancers Abstract No. 317
	Poster Section:18 Board Number:383 Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors Abstract No. 2161
April 29th 2:00PM-5:00PM	Poster Section:21 Board Number:10 HDM2006, A Novel and Potent HPK1 PROTAC, Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition Abstract No. 5632

2025ASCO

The American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from 30 May to 3 June 2025, is the world's leading professional scientific organization in oncology and is one of the largest and most prestigious global oncology conferences. It serves as a premier platform for the presentation of cutting-edge research and clinical trial data in cancer care.

Huadong Medicine will be showcasing its proprietary anti-tumour drug HDM2025 through a poster presentation at this prestigious event. This innovative therapeutic agent demonstrates potent and selective pan-KRAS targeting capabilities, marking a significant advancement in the development of oncology therapeutics.

2025H1: Poster at ASCO
June 2nd 1:30PM-4:30PM	Poster Section:15 Board Number:428 Discovery of Potent Degraders of pan-KRAS Based on a Novel KRAS Binder

2025ADA

The 85th American Diabetes Association (ADA) Scientific Sessions, a major international academic event in the field of diabetes, will take place in Chicago, USA, from June 20-23, 2025. This esteemed congregation will bring together clinicians, researchers, educators and industry leaders to advance discussions on diabetes-related basic research, clinical practice, prevention strategies and technological innovation. At this landmark conference, Huadong Medicine will present groundbreaking achievements: The company's self-developed GLP-1/GIP dual-target long-acting agonist, HDM1005 Injection, has been selected for an Oral Presentation, emphasizing its innovative therapeutic potential. The poster presentations will feature the company's proprietary research on HDM1002-102, an oral small-molecule GLP-1 agonist, along with Phase III clinical trial results of Semaglutide Injection, highlighting Huadong Medicine' leadership in advancing diabetes care.

2025H1: Oral Presentation&Posters at ADA
June 20th 5:45PM-6:00PM	Abstract Number：142-OR Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
June 22nd 12:30PM-1:30PM	Abstract Number：737-P HDM1002 in Chinese Adults with Overweight or Obesity-A Randomized, Placebo-Controlled, Four-Week, Phase 1b Study
	Abstract Number：839-P Efficacy and Safety of HDG1901 vs Ozempic® in Patients with Type 2 Diabetes (T2D): A Randomized, Open-label, Bioequivalence Phase 3 Trial

2025EASL

Concurrently, Huadong Medicine' subsidiary Doer Biologics will present groundbreaking clinical research data at the European Association for the Study of the Liver (EASL) Annual Congress 2025, a leading international event in hepatology, taking place in Amsterdam, the Netherlands, from 7 to 10 May. The company will be showing data from its New Zealand-based multi-ascending dose (MAD) study of DR10624-101, an Fc fusion protein drug developed using its proprietary MultipleBody® platform technology, in a poster presentation. DR10624 is the "first-in-class" and the world's first tri-target agonist activating three critical receptors: the glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and FGFR1c/Klothoβ (FGF21R). This positions it as a pioneering advancement in the field of metabolic and liver disease therapeutics.

2025H1: Posters at EASL
May 7th 8:30AM-4:00PM	Abstract identifier: LBP-003/FRI-365 Late breaker DR10624, a first-in-class, FGF21 receptor (FGF21R)/glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) triple agonist rapidly and significantly reduced liver fat in obese subjects with modest hypertriglyceridemia: a 12-week randomized, placebo-controlled, double-blind, multi-center trial
May 9th 8:30AM-5:00PM	DR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotype

Huadong Medicine's participation in a series of leading international academic conferences to highlight its proprietary innovations underscores the growing global recognition of its pioneering R&D capabilities. In the future, Huadong Medicine will continue to commit to its core philosophy of 'Scientific Research-based and Patient-centered' by pursuing proprietary research and strategic collaborations to expand innovative product pipeline,aim to become a powerful international pharmaceutical enterprise driven by scientific research innovation.

Statements

1.This news article is intended to share frontline updates on the R&D progress of the company (or its partners) and is not for advertising purposes. The information provided is not directed at patients and is for reference by healthcare professionals only.

2.This press release does not endorse or recommend any specific pharmaceutical product and/or indication.

3.The information contained herein is for reference only and shall be subject to the documents officially released by the company on the Shenzhen Stock Exchange. Neither this press release nor company announcements shall replace professional medical guidance or be construed as diagnostic or treatment advice. For specific disease-related information, please consult physicians or other qualified healthcare professionals.

4.As of the date of this release, HDM1002, HDM1005, HDM2006, HDM2012, HDM2017, HDM2020, HDM2022, HDM2025, DR10624, and HDG1901 (the company’s semaglutide injection) have not been approved for marketing by the National Medical Products Administration (NMPA).

5.This press release may contain forward-looking statements. Such statements inherently involve risks and uncertainties. Terms such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and similar expressions, when related to the Company, constitute forward-looking statements. The Company is under no obligation to continuously update these predictive statements.

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understandings of the Company’s management regarding future events at the time of publication. They are not guarantees of future performance and are subject to risks, uncertainties, and other factors beyond the Company’s control. Actual results may differ materially from those expressed or implied due to changes in the Company’s business, competitive landscape, and political, economic, legal, and social conditions.

The Company, its directors, employees, and agents shall not be liable for (a) any obligation to correct or update forward-looking statements contained herein; or (b) any consequences arising from the failure of such forward-looking statements to materialize or their inaccuracy.v